Antibody-Based Immunotherapeutic Strategies for COVID-19

Jamal Hussen,Abdullah I A Al-Mubarak,Mahmoud Kandeel,Maged Gomaa Hemida

doi:10.3390/pathogens9110917

Jamal Hussen, Abdullah I A Al-Mubarak + Show 2 more

Open Access

https://doi.org/10.3390/pathogens9110917

Copy DOI

Journal: Pathogens	Publication Date: Nov 5, 2020
Citations: 12	License type: CC BY 4.0

Affiliation: King Faisal University, Kafrelsheikh University

Abstract

Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.

Highlights

SARS-CoV-2 is the third zoonotic coronavirus that emerged in the last decade after the SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 [1,2]
The current study aims to review the main clinical trials registered on 30 trials are currently taking place mostly in the U.S, China, and Europe, evaluating the use of mAb
This study found higher titers of antibodies against the surface spike protein receptor-binding domain (RBD) compared to the internal nucleocapsid protein (NP) antigen. [39]

Summary

Introduction

SARS-CoV-2 is the third zoonotic coronavirus that emerged in the last decade after the SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 [1,2] They have the criteria of a high rate of infection and spread among a close contact population [3,4,5,6]. The majority of individuals with COVID-19 exhibit only mild-to-moderate symptoms, about 15% of infected people have a progressive course of infection Some of these cases develop a severe form of the disease characterized by acute respiratory distress syndrome (ARDS) and septic shock [1,2,7,8,9,10,11].

Methods

Results

Conclusion